Promising Clinical Trial Results From Flex Pharma
On November 6, Flex Pharma Inc. (FLKS) reported positive stage 2 clinical trial results for a new drug to treat cramps and spasticity associated with a variety of neurological disorders. Positive topline data for FLX-787 indicates that significant improvement of pain and cramping is possible for those suffering from multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth (CMT). Flex Pharma is a clinical-stage biotechnology company.
Rocket Tickers detected the event and sent an alert at 7:00 am. The next trade took place at 8:04 am for $3.51. Regular market trading opened at $3.65. The stock price continued to trend up over the next few days on the positive news. Flex Pharma closed at $3.81 on November 13.
Visit the Knowledge Center for more information about clinical trials and how to trade them.
Subscribe here if you would like to start receiving these signals in real-time and start trading!